Wedbush Equities Analysts Lower Earnings Estimates for TLX

Key Points

• Wedbush Equities has lowered its Q4 2025 earnings estimate for Telix Pharmaceuticals from $0.04 to $0.03 per share, although it maintains an "Outperform" rating with a price target of $22.00.
• Various equities analysts remain mixed on Telix Pharmaceuticals, with ratings ranging from "Strong Buy" to "Sell", and a consensus price target currently standing at $21.00.
• The stock recently saw a gain of 5.2% and is currently trading around $10.04, significantly lower than its 52-week high of $30.36.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Research analysts at Wedbush reduced their Q4 2025 earnings per share estimates for Telix Pharmaceuticals in a report released on Tuesday, October 14th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.03 per share for the quarter, down from their previous forecast of $0.04. Wedbush has a "Outperform" rating and a $22.00 price objective on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share. Wedbush also issued estimates for Telix Pharmaceuticals' Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.22 EPS, Q1 2027 earnings at $0.09 EPS, Q2 2027 earnings at $0.09 EPS and Q3 2027 earnings at $0.10 EPS.

Other equities analysts have also issued reports about the company. Citigroup started coverage on Telix Pharmaceuticals in a report on Thursday, September 18th. They set a "buy" rating and a $22.00 target price for the company. HC Wainwright decreased their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, September 10th. Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. Canaccord Genuity Group raised Telix Pharmaceuticals to a "strong-buy" rating in a report on Monday, October 6th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Up 5.2%

NASDAQ:TLX opened at $10.04 on Wednesday. The stock has a 50 day moving average of $10.35 and a 200-day moving average of $14.22. Telix Pharmaceuticals has a 52 week low of $8.93 and a 52 week high of $30.36.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $213,000. Jane Street Group LLC acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $564,000. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $975,000. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $3,037,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.